Makes large-volume IV fluids and injectable antibiotics at a single government-approved factory in Chengdu, selling directly to Chinese hospitals.
At a glance
- Depends onDownstream position: depends on 11 industries, supplies 6
- Scale
Makes large-volume IV fluids and injectable antibiotics at a single government-approved factory in Chengdu, selling directly to Chinese hospitals.
What this company is and how it runs — written from structure, not news.
Sichuan Kelun Pharmaceutical makes large-volume IV solutions and injectable antibiotics at a single facility in Chengdu, where both product lines share the same pharmaceutical-grade water systems and aseptic filling environment, which means antibiotic-containing IV solutions can be compounded in-line without an external sterile transfer step that would otherwise introduce a contamination risk. Because hospitals in Sichuan's procurement system have configured their connector types, flow rates, and cold-chain storage around this facility's specific output, switching to another supplier would require clinical staff retraining and a multi-month regulatory registration transfer — so demand stays anchored to the Chengdu complex even when provincial governments push prices down. Adding capacity means building and validating new aseptic filling lines, but each one must complete NMPA's extended sterility-testing cycle before it can produce a single commercial unit, and no amount of capital spending shortens that timeline. The same shared infrastructure that makes the in-line compounding possible is also the single point of failure: a sterility problem on the antibiotic side can force the regulator to shut down the IV solution lines at the same time, since the water systems and environmental controls run through both.
How does this company make money?
The company earns money by selling IV solution bags and antibiotic vials to hospital procurement departments on a per-unit basis. Prices are not set freely — they are decided through provincial government tender processes, and annual supply volumes are locked in through purchasing agreements that set quotas in advance.
What makes this company hard to replace?
Hospital pharmacies are set up for the specific connector types and flow rates on this factory's IV bags, and switching to a different supplier means retraining clinical staff on new equipment. Moving to a new supplier also triggers a multi-month NMPA registration transfer review that cannot be skipped. On top of that, the cold-chain storage and refrigerated logistics partnerships that regional distributors have built around this factory's products cannot simply be redirected to someone else overnight.
What limits this company?
The factory can only produce as much as its validated filling lines allow, and each line has to pass its own lengthy sterility tests set by NMPA before it can make a single product for sale. Adding a new line increases capacity eventually, but no amount of money makes NMPA's testing run faster — the timeline is fixed by regulation, not by resources.
What does this company depend on?
The factory cannot run without pharmaceutical-grade water treatment systems that meet Chinese GMP standards, sterile glass vials and plastic IV bags from medical packaging suppliers, active pharmaceutical ingredients for antibiotics sourced from Chinese chemical manufacturers, NMPA manufacturing licences for sterile injectable products, and temperature-controlled distribution networks that reach China's hospital system.
Who depends on this company?
Chinese public hospitals would face IV fluid shortages during busy periods if this factory stopped, because no other domestic supplier has the same sterile production capacity to fill the gap quickly. Private clinics in Sichuan province would lose access to locally made antibiotic formulations and would have to pay more for imported alternatives. Regional pharmaceutical distributors would have to find IV solutions from factories on China's coast, raising their costs and slowing delivery times.
How does this company scale?
Adding more automated filling lines can increase how many bags and vials the factory produces, and the packaging side of that process is relatively straightforward to replicate. What does not get easier as the company grows is the wait for NMPA to validate each new line through its extended sterility testing — that bottleneck stays the same size no matter how big the company gets.
What external forces can significantly affect this company?
China's healthcare reform policies give provincial governments the power to negotiate IV solution prices directly with suppliers, which puts pressure on how much the company can charge per unit. At the same time, an aging population means more hospital admissions and higher demand for IV fluids overall. Environmental rules in Sichuan province limit how pharmaceutical wastewater can be discharged, requiring the factory to invest in upgraded water treatment systems.
Where is this company structurally vulnerable?
The IV fluid lines and the antibiotic lines share the same water systems and air controls inside the Chengdu complex. If NMPA found a sterility problem on the antibiotic side and ordered a shutdown, the IV fluid lines would go down at the same time — because the same infrastructure runs both. One contamination event could stop all output at once, and the factory could not restart until NMPA's full validation process finished again.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Current close sits in the upper portion of the 14-week high-low range; current close sits in the upper portion of its 20-week Bollinger Bands; RSI sits above its 20-week recent mean (Bollinger %B applied to RSI).
Three observations have aligned: recent 10-week Average True Range is above its prior 10-week window (ATR expansion), the volatility-expansion-breakout observation is firing, and current-week volume is well above the 30-week average.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
What the company actually pays, and whether its own cash supports it.
The reported statements, read against the company's own industry.
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Three observations co-occur: long-term debt decreased year-over-year in each of the last four fiscal years, total cash at MRQ is at least equal to total debt, and the industry-benchmarked equity ratio is in its elevated range. The configuration describes past LT-debt reduction consistency alongside cash-vs-debt position and equity-heavy capital structure.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph